|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5985846A
(en)
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
IL133510A0
(en)
|
1998-04-15 |
2001-04-30 |
Univ New York State Res Found |
Selective regulation of adenovirus production
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US5989910A
(en)
|
1998-08-03 |
1999-11-23 |
University Of Lausanne |
Potent genetic switch allowing regulated gene expression in eukaryotic cells
|
|
US6423544B1
(en)
|
1998-12-31 |
2002-07-23 |
Chiron Corporation |
Compositions and methods for producing recombinant virions
|
|
MY123548A
(en)
|
1999-11-08 |
2006-05-31 |
Shell Int Research |
Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
|
WO2002066620A2
(de)
|
2001-02-21 |
2002-08-29 |
Stefan Kochanek |
Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
|
|
CA2485939C
(en)
|
2002-05-29 |
2013-10-29 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
WO2005106046A1
(en)
|
2004-05-03 |
2005-11-10 |
Stefan Kochanek |
Modified viral vector particles
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
WO2007133797A2
(en)
|
2006-05-15 |
2007-11-22 |
Paratek Pharmaceuticals, Inc. |
Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
|
|
DK2150617T3
(en)
|
2007-06-04 |
2015-01-12 |
Regeneron Pharma |
Regions with increased expression and stability
|
|
US8852926B2
(en)
|
2007-10-25 |
2014-10-07 |
Board Of Trustees Of Southern Illinois University |
Genetic selection system for identification of MicroRNA target genes
|
|
DE102009003439A1
(de)
|
2009-02-05 |
2010-08-26 |
Cevec Pharmaceuticals Gmbh |
Neue permanente humane Zelllinie
|
|
US8734809B2
(en)
*
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2011126808A2
(en)
*
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9839696B2
(en)
|
2010-04-30 |
2017-12-12 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
JP5928843B2
(ja)
|
2010-08-16 |
2016-06-01 |
ツェヴェック ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
|
|
EP2662451A1
(en)
|
2012-05-07 |
2013-11-13 |
Stefan Kochanek |
Nucleic acid construct and use of the same
|
|
EP2711428A1
(en)
|
2012-09-21 |
2014-03-26 |
Lonza Biologics plc. |
Site-specific integration
|
|
EP3030656B1
(en)
|
2013-08-06 |
2018-08-22 |
Lonza Biologics Plc. |
Means and methods for the generation of mammalian producer cells for the production of recombinant proteins
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
JP6756700B2
(ja)
|
2014-03-18 |
2020-09-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
|
|
EP3209785B1
(en)
|
2014-10-23 |
2019-07-31 |
Regeneron Pharmaceuticals, Inc. |
Novel cho integration sites and uses thereof
|
|
EP3042952A1
(en)
|
2015-01-07 |
2016-07-13 |
CEVEC Pharmaceuticals GmbH |
O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
EP3205719A1
(en)
|
2016-02-15 |
2017-08-16 |
CEVEC Pharmaceuticals GmbH |
Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
|
|
GB201603577D0
(en)
|
2016-03-01 |
2016-04-13 |
Oxford Genetics Ltd |
Promoter
|
|
WO2017173043A1
(en)
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
BR112018071283A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
US20190171188A1
(en)
|
2016-08-10 |
2019-06-06 |
Lonza Inc. |
Biopharmaceutical Batch Recipe Review by Exception
|
|
JP7112414B2
(ja)
|
2017-02-08 |
2022-08-03 |
フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ |
網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターsynp88
|
|
CN119242587A
(zh)
|
2017-02-17 |
2025-01-03 |
隆萨有限公司 |
难以表达的蛋白质的多位点特异性整合细胞
|
|
WO2018150271A1
(en)
|
2017-02-17 |
2018-08-23 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
|
CN110419011A
(zh)
|
2017-03-17 |
2019-11-05 |
龙沙有限公司 |
自动化批量数据分析
|
|
EP3601581B1
(en)
|
2017-03-22 |
2025-04-30 |
Ultragenyx Pharmaceutical Inc. |
CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS
|
|
EP3382014A1
(en)
|
2017-03-29 |
2018-10-03 |
CEVEC Pharmaceuticals GmbH |
Recombinant glycoproteins with reduced antennary fucosylation
|
|
GB201705927D0
(en)
|
2017-04-12 |
2017-05-24 |
Oxford Genetics Ltd |
Vector
|
|
BR112019021595A2
(pt)
|
2017-04-18 |
2020-05-12 |
Glaxosmithkline Intellectual Property Development Limited |
Célula produtora de vírus adeno-associado, vetor de ácido nucleico, métodos para produzir uma linhagem de células de empacotamento estável de vírus adeno-associado e uma partícula de vetor de vírus adeno-associado com defeito de replicação, célula de empacotamento de vírus adeno-associado, e, partícula de vetor de vírus adeno-associado com defeito de replicação.
|
|
CN110892064A
(zh)
|
2017-07-25 |
2020-03-17 |
牛津遗传学有限公司 |
腺病毒载体
|
|
EP3441471A1
(en)
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
EP3456822A1
(en)
|
2017-09-19 |
2019-03-20 |
CEVEC Pharmaceuticals GmbH |
Inducible aav rep genes
|
|
US12123027B2
(en)
|
2017-10-12 |
2024-10-22 |
Ascend Advanced Therapies Limited |
Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV
|
|
CN111386126B
(zh)
|
2017-10-25 |
2024-01-30 |
Nouscom股份公司 |
真核细胞系
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
GB201800903D0
(en)
|
2018-01-19 |
2018-03-07 |
Oxford Genetics Ltd |
Vectors
|
|
WO2019157239A1
(en)
|
2018-02-08 |
2019-08-15 |
David Kiewlich |
Plasmid vectors for expression of large nucleic acid transgenes
|
|
GB201802122D0
(en)
|
2018-02-09 |
2018-03-28 |
Univ Oxford Innovation Ltd |
Product and use
|
|
GB201814590D0
(en)
|
2018-09-07 |
2018-10-24 |
Oxford Biomedica Ltd |
Viral vector production system
|
|
EP3597172A1
(en)
|
2018-07-16 |
2020-01-22 |
Kao Germany GmbH |
Hair treatment composition
|
|
WO2020033842A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
|
EP3841193A1
(en)
|
2018-08-21 |
2021-06-30 |
Lonza Ltd. |
A process for creating reference data for predicting concentrations of quality attributes
|
|
GB201814141D0
(en)
|
2018-08-30 |
2018-10-17 |
Univ Oxford Innovation Ltd |
Method and compositions for producing a virus
|
|
JP7549582B2
(ja)
|
2018-10-01 |
2024-09-11 |
ロンザ リミテッド |
予測可能かつ安定な導入遺伝子発現を有するssi細胞および形成の方法
|
|
US20210388343A1
(en)
|
2018-10-17 |
2021-12-16 |
Children's Medical Research Institute |
Nucleic acid molecules and methods for aav vector selection
|
|
GB201816919D0
(en)
|
2018-10-17 |
2018-11-28 |
Glaxosmithkline Ip Dev Ltd |
Adeno-associated viral vector producer cell lines
|
|
KR102559149B1
(ko)
|
2018-10-26 |
2023-07-24 |
에프. 호프만-라 로슈 아게 |
재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
|
|
JP7598864B2
(ja)
|
2018-12-21 |
2024-12-12 |
ロンザ ウォーカーズヴィル,インコーポレーテッド |
ウイルスベクターの自動産生方法
|
|
EP3980544A1
(en)
|
2018-12-21 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Targeted integration of nucleic acids
|
|
SG11202106217TA
(en)
*
|
2018-12-21 |
2021-07-29 |
Lonza Walkersville Inc |
Adeno-associated virus (aav) producer cell line and related methods
|
|
GB201901571D0
(en)
|
2019-02-05 |
2019-03-27 |
Oxford Genetics Ltd |
Inducible AAV sysyem
|
|
GB201902068D0
(en)
|
2019-02-14 |
2019-04-03 |
Cambridge Entpr Ltd |
Methods of reactivating proliferative capacity non-proliferative tissues
|
|
US20220154174A1
(en)
|
2019-03-08 |
2022-05-19 |
Oxford Genetics Limited |
Method of Selecting for Antibodies
|
|
US12018288B2
(en)
|
2019-04-12 |
2024-06-25 |
Ultragenyx Pharmaceutical Inc. |
Engineered producer cell lines and methods of making and using the same
|
|
AU2020275884B2
(en)
|
2019-05-16 |
2026-05-14 |
Trustees Of Boston University |
Regulated synthetic gene expression systems
|
|
EP3976806A1
(en)
|
2019-05-30 |
2022-04-06 |
Solidus Biosciences, Inc. |
Recombinant herpesvirales vector
|
|
KR20220118436A
(ko)
|
2019-12-19 |
2022-08-25 |
론자 워커스빌 아이엔씨. |
바이러스 벡터의 자동화된 생산
|
|
EP4090750A4
(en)
|
2020-01-17 |
2024-03-13 |
Asklepios Biopharmaceutical, Inc. |
RECOMBINANT AAV PRODUCTION
|
|
GB202001484D0
(en)
|
2020-02-04 |
2020-03-18 |
Oxford Genetics Ltd |
DNA amplification method
|
|
AU2021217799A1
(en)
|
2020-02-04 |
2022-07-21 |
Oxford Genetics Limited |
Process for making adenoassociated viral vectors
|
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
KR20230017799A
(ko)
|
2020-05-15 |
2023-02-06 |
아이벡스솔, 아이엔씨. |
세포 및 유전자 요법을 위한 안정한 바이러스 벡터 생산자 세포를 생산하기 위한 조성물 및 방법
|
|
CN113699147B
(zh)
|
2020-05-22 |
2023-06-09 |
深圳市深研生物科技有限公司 |
基于四环素和Cumate的共调控序列
|
|
WO2022020712A1
(en)
|
2020-07-24 |
2022-01-27 |
Regents Of The University Of Minnesota |
Cell lines for recombinant aav production and aav-implemented protein production
|
|
US20230357794A1
(en)
|
2020-08-21 |
2023-11-09 |
Oxford Genetics Limited |
Process for making a recombinant aav library
|
|
GB202013060D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Cell line
|
|
GB202013057D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Method of making recombinant aavs
|
|
EP4006141A1
(en)
*
|
2020-11-25 |
2022-06-01 |
CEVEC Pharmaceuticals GmbH |
Method for the production of aav
|
|
EP4291665A1
(en)
|
2021-02-11 |
2023-12-20 |
Lonza Houston Inc. |
Adeno-associated virus (aav) production
|
|
JP2024517104A
(ja)
|
2021-04-19 |
2024-04-19 |
オックスフォード ジェネティクス リミテッド |
Careエレメントを用いたdna増幅方法
|
|
US20230257831A1
(en)
|
2021-09-01 |
2023-08-17 |
Oxford Genetics Limited |
Method for determining aav titre
|
|
AR127674A1
(es)
|
2021-10-18 |
2024-02-21 |
Regeneron Pharma |
Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
|
|
CN118159660A
(zh)
|
2021-10-18 |
2024-06-07 |
瑞泽恩制药公司 |
多核苷酸的受控转录
|
|
WO2023173105A2
(en)
|
2022-03-10 |
2023-09-14 |
Saliogen Therapeutics, Inc. |
Tetracycline inducer/repressor system and simplified viral particle production
|